AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
03 Nov 2014 03:00 PM
RNS
Total Voting Rights
03 Nov 2014 07:00 AM
RNS
AZ COMPLETES STRATEGIC TRANSACTION WITH ALMIRALL
30 Oct 2014 07:00 AM
RNS
US FDA APPROVES ONCE-DAILY XIGDUOT XR TABLETS
24 Oct 2014 12:10 PM
RNS
Olaparib receives positive CHMP opinion
02 Oct 2014 03:30 PM
RNS
Director/PDMR Shareholding
01 Oct 2014 04:00 PM
RNS
Total Voting Rights
29 Sep 2014 07:00 AM
RNS
ASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ESMO
26 Sep 2014 11:15 AM
RNS
Positive CHMP Opinion for MOVENTIG (naloxegol)
16 Sep 2014 04:27 PM
RNS
FDA Approves MOVANTIK (naloxegol) Tablets
16 Sep 2014 07:00 AM
RNS
AZ AND LILLY ALLIANCE TO DEVELOP BACE INHIBITOR
10 Sep 2014 04:30 PM
RNS
Director/PDMR Shareholding
01 Sep 2014 04:00 PM
RNS
Total Voting Rights
19 Aug 2014 07:00 AM
RNS
US DOJ Closes Investigation into Plato
19 Aug 2014 07:00 AM
RNS
CAZ-AVI PHASE III RESULTS
14 Aug 2014 07:00 AM
RNS
TRALOKINUMAB PHASE III START IN SEVERE ASTHMA
13 Aug 2014 07:00 AM
RNS
PHASE III RESULTS LESINURAD COMBINATION THERAPY
04 Aug 2014 01:00 PM
RNS
Director/PDMR Shareholding
01 Aug 2014 02:00 PM
RNS
Total Voting Rights
01 Aug 2014 11:30 AM
RNS
Director/PDMR Shareholding
31 Jul 2014 07:00 AM
RNS
AstraZeneca Pipeline
31 Jul 2014 07:00 AM
RNS
Second Quarter & Half Year Results 2014
30 Jul 2014 09:00 AM
RNS
Notice of Results
30 Jul 2014 07:00 AM
RNS
STRATEGIC RESPIRATORY TRANSACTION WITH ALMIRALL
01 Jul 2014 03:30 PM
RNS
Total Voting Rights
01 Jul 2014 12:00 PM
RNS
Director/PDMR Shareholding
26 Jun 2014 02:00 PM
RNS
Director/PDMR Shareholding
26 Jun 2014 07:00 AM
RNS
FDA Advisory Committee votes on olaparib
24 Jun 2014 05:30 PM
RNS
Publication of Prospectus
18 Jun 2014 11:00 AM
RNS
Holding(s) in Company
18 Jun 2014 10:00 AM
RNS
Director/PDMR Shareholding
18 Jun 2014 10:00 AM
RNS
Director/PDMR Shareholding
13 Jun 2014 03:00 PM
RNS
Clarification of AXA shareholding in AstraZeneca
13 Jun 2014 07:00 AM
RNS
FDA AdCom recommends no CV trial for PAMORA class
12 Jun 2014 07:00 AM
RNS
ASTRAZENECA IN-LICENSES SYNAIRGEN'S SNG001
11 Jun 2014 07:00 AM
RNS
AZ TO PRESENT NEW DATA AT ADA
03 Jun 2014 02:30 PM
RNS
ASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ASCO
03 Jun 2014 07:00 AM
RNS
ASTRAZENECA UPDATES ON ONCOLOGY PIPELINE AT ASCO
02 Jun 2014 02:00 PM
RNS
Blocklisting Interim Review
02 Jun 2014 01:30 PM
RNS
Total Voting Rights
27 May 2014 04:14 PM
BZW
Form 8.3 - Astrazeneca Plc
27 May 2014 03:07 PM
BZW
Form 8.3 - AstraZeneca Plc
27 May 2014 07:00 AM
RNS
STATEMENT REGARDING PFIZER WITHDRAWAL
23 May 2014 03:16 PM
BZW
Form 8.3 - Astrazenica Plc
23 May 2014 03:13 PM
BZW
Form 8.3 - AstraZeneca Plc
23 May 2014 01:45 PM
BZW
Form 8.3 - Astrazeneca Plc
23 May 2014 01:43 PM
BZW
Form 8.3 - AstraZeneca PLC
23 May 2014 11:00 AM
RNS
Rule 2.10 Announcement
22 May 2014 03:22 PM
BZW
Form 8.3 - AstraZeneca Plc
22 May 2014 03:01 PM
BZW
Form 8.3 - AstraZeneca Plc
22 May 2014 02:15 PM
BZW
Form 8.3 - AstraZeneca PLC

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings